Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dan Calvo, Erik Wallden, Sid Taubenfeld, Bill Dubiel

Premium

Gyros AB has appointed Dan Calvo president and CEO, replacing Erik Wallden.

Calvo was most recently president and CEO of Oncimmune USA. He was previously president and CEO of Assay Designs and Cellomics.


Sid Taubenfeld has joined Arrayit's board of directors.

Taubenfeld has served as an analyst for a number of Wall Street hedge funds, including Balyasny Asset Management, RH Capital, and PAW Partners. Additionally, Taubenfeld served as director of communications and strategic initiatives for Celsion Corp.


CyVek has appointed Bill Dubiel chief commercial officer.

Dubiel joins CyVek from Roche Tissue Diagnostics where he was vice president of sales. Before that he held senior positions at Bayer Healthcare, Chiron, and Ciba-Corning Diagnostics.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.